摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氟吲唑-3-羧酸 | 1077-96-9

中文名称
5-氟吲唑-3-羧酸
中文别名
5-氟-1H-吲唑-3-甲酸
英文名称
5-fluoro-1H-indazole-3-carboxylic acid
英文别名
——
5-氟吲唑-3-羧酸化学式
CAS
1077-96-9
化学式
C8H5FN2O2
mdl
MFCD03840628
分子量
180.138
InChiKey
XFHIMKNXBUKQNS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    299 °C
  • 沸点:
    445.9±25.0 °C(Predicted)
  • 密度:
    1.610±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    66
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S45,S60,S61
  • WGK Germany:
    3
  • RTECS号:
    CY1576350
  • 海关编码:
    2933990090
  • 包装等级:
    III
  • 危险类别:
    3
  • 危险品运输编号:
    UN 2811 6.1/PG 3
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:a9b2c4486f7854f440c0ab38515cb35f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Fluoro-1H-indazole-3-carboxylic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-Fluoro-1H-indazole-3-carboxylic acid
CAS number: 1077-96-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5FN2O2
Molecular weight: 180.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

5-氟吲唑-3-羧酸是一种医药中间体。它可以通过将5-氟吲哚醌作为原料,在一步反应中制备得到。有文献报道,该化合物可用于制备选择性雄激素受体降解剂(SARD),适用于治疗前列腺癌。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-氟吲唑-3-羧酸lithium carbonate 、 Selectfluor 作用下, 以 二氯甲烷 为溶剂, 反应 2.0h, 以48%的产率得到3,5-difluoro-1H-indazole
    参考文献:
    名称:
    [EN] SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF
    [FR] LIGANDS DE COMPOSÉS DE DÉGRADATION SÉLECTIFS DE RÉCEPTEURS DES ANDROGÈNES (SARD) ET PROCÉDÉS D'UTILISATION ASSOCIÉS
    摘要:
    这项发明涉及选择性雄激素受体降解剂(SARD)化合物,包括杂环环和药物组合物,以及在治疗前列腺癌、晚期前列腺癌、去势抵抗性前列腺癌、三阴性乳腺癌、其他表达雄激素受体的癌症、雄激素性脱发或其他高雄激素皮肤疾病、肯尼迪病、肌萎缩性侧索硬化(ALS)、腹主动脉瘤(AAA)和子宫肌瘤中的应用,以及用于降低受试者中雄激素受体全长(AR-FL)包括致病性或耐药突变、AR剪接变体(AR-SV)和AR的致病性多谷氨酸(polyQ)多态性的水平的方法。
    公开号:
    WO2020051344A1
  • 作为产物:
    描述:
    5-氟靛红 在 sodium hydroxide 、 硫酸 、 sodium nitrite 、 盐酸 、 tin(II) chloride dihdyrate 作用下, 以 为溶剂, 反应 19.5h, 生成 5-氟吲唑-3-羧酸
    参考文献:
    名称:
    作为人中性粒细胞弹性蛋白酶抑制剂的 N-苯并吲哚衍生物的优化
    摘要:
    人类中性粒细胞弹性蛋白酶 (HNE) 是治疗肺部疾病的重要治疗靶点。以前,我们将新型N-苯甲酰基吲唑衍生物鉴定为有效、竞争性和假不可逆的 HNE 抑制剂。在这里,我们报告了这些抑制剂的进一步开发,与我们之前的先导相比,这些抑制剂具有更高的效力、蛋白酶选择性和稳定性。在吲唑的 5 位引入各种取代基产生了有效的抑制剂20f (IC 50 ∼10 nM),而在 3 位的修饰产生了该系列中最有效的化合物,即 3-CN 衍生物5b (IC 50= 7纳米);与其他丝氨酸蛋白酶相比,这两种衍生物对 HNE 均表现出良好的稳定性和特异性。选定的N-苯甲酰基吲唑与 HNE 结合域的分子对接表明抑制活性取决于配体-酶复合物的几何形状。事实上,配体形成 Michaelis 复合物的能力以及 Hys57、Asp102 和 Ser195 之间质子转移的有利条件都会影响活性。
    DOI:
    10.1021/jm400742j
点击查看最新优质反应信息

文献信息

  • Development of Potent Serotonin-3 (5-HT3) Receptor Antagonists. II. Structure-Activity Relationships of N-(1-Benzyl-4-methylhexahydro-lH-1,4-diazepin-6-yl)carboxamides.
    作者:Hiroshi HARADA、Toshiya MORIE、Yoshimi HIROKAWA、Hideo TERAUCHI、Iwao FUJIWARA、Naoyuki YOSHIDA、Shiro KATO
    DOI:10.1248/cpb.43.1912
    日期:——
    reflex in rats are described. Heteroaromatic rings such as pyrrole, thiophene, furan, pyridine, pyridazine, 1,2-benzisoxazole, indole, quinoline, and isoquinoline rings showed weak 5-HT3 receptor antagonistic activity. Within this series, use of the 1H-indazole ring as an aromatic moiety led to a substantial increase of the activity; the 1H-indazolylcarboxamides 54, 57, 97, and 102 showed potent 5-HT3
    我们对4-氨基-5-氯-2-乙氧基苯甲酰胺的研究导致发现N-(1,4-二甲基六氢-1H-1,4-二氮杂-6-6基)苯甲酰胺9和1-苄基-4 -甲基六氢-1H-1,4-二氮杂analogue类似物10是有效的血清素3(5-HT3)受体拮抗剂。描述了结构和活性关系(SAR)研究9和10的芳香核对大鼠von Bezold-Jarisch反射的抑制作用。杂芳族环,如吡咯,噻吩,呋喃,吡啶,哒嗪,1,2-苯并恶唑环,吲哚,喹啉和异喹啉环显示弱的5-HT3受体拮抗活性。在这个系列中,使用1H-吲唑环作为芳族部分会导致活性的大幅提高。1H-吲唑基羧酰胺54、57、97和102显示出有效的5-HT3受体拮抗活性。
  • [EN] NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES TÉTRAHYDROPYRIDOPYRIMIDINES POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
    申请人:HOFFMANN LA ROCHE
    公开号:WO2018083106A1
    公开(公告)日:2018-05-11
    The present invention provides novel compounds having the general formula (I) wherein R1, R2 and Z are as described herein, compositions including the compounds and methods of using the compounds.
    本发明提供了具有一般式(I)的新化合物,其中R1、R2和Z如本文所述,包括这些化合物的组合物和使用这些化合物的方法。
  • [EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS D'ALCYNYLE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
    申请人:HOFFMANN LA ROCHE
    公开号:WO2015025025A1
    公开(公告)日:2015-02-26
    The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.
    这项发明涉及以下式的化合物(0):其中Q,A1-A8,R4和R5分别具有如本文所述的含义。式(0)的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度活化的疾病和紊乱中是有用的。
  • COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT
    申请人:GILEAD SCIENCES, INC.
    公开号:US20130273037A1
    公开(公告)日:2013-10-17
    Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
    提供用于治疗病毒感染的化合物、药用可接受的盐和酯及其组合物。这些化合物和组合物对于治疗Pneumovirinae病毒感染很有用。提供的化合物、组合物和方法特别适用于治疗人类呼吸道合胞病毒感染。
  • Monoacylglycerol Lipase Modulators
    申请人:Janssen Pharmaceutica NV
    公开号:US20200102303A1
    公开(公告)日:2020-04-02
    Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.
    化合物的结构式(I)和结构式(II),含有它们的药物组合物,制备它们的方法,以及使用它们的方法,包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法,例如与疼痛、精神障碍、神经障碍(包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症)、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。
查看更多